Document is current
Any future updates will be listed below
-
Authors
Soto, Claudio https://orcid.org/0000-0002-3412-0524
Mollenhauer, Brit
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
Kang, Un Jung https://orcid.org/0000-0002-5970-6839
Alcalay, Roy N. https://orcid.org/0000-0002-5717-4875
Standaert, David https://orcid.org/0000-0003-2921-8348
Trenkwalder, Claudia https://orcid.org/0000-0001-6407-1199
Marek, Kenneth
Galasko, Douglas
Poston, Kathleen https://orcid.org/0000-0003-3424-7143
-
Funding
Funding for this research was provided by:
Alzheimer's Association (ZEN24-1069572, SG-23-1061717)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS131658, U01NS113851 and U01NS122419, U01NS100610, NS115114)
- License Information
-
More Information
Article History
Received: 28 May 2024
Accepted: 12 December 2024
First Online: 30 January 2025
Competing interests
: C.S. is a founder, chief scientific officer, shareholder and member of the board of directors of Amprion, a biotechnology company that focuses on the commercial use of seed amplification assays for high-sensitivity detection of misfolded protein aggregates involved in various neurodegenerative diseases. The University of Texas Health Science Center has licensed patents to Amprion. B.M. is scientific advisor to Amprion and has received honoraria for consultancy and/or educational presentations from GE, Bial, Roche, Biogen and AbbVie. O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy or speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. U.J.K. is on the scientific advisory board of Amprion and consults for UCB, NurrOn and HanAll. R.N.A. has received consulting fees from Biogen, Biohaven, Capsida, Gain Therapeutics, Sanofi, Servier, Takeda and Vanqua Bio. D.S. is a consultant for or received honoraria from Abbvie, Alnylam Pharmaceutics, Appello, Biohaven Pharmaceuticals, BlueRock Therapeutics, Coave Therapeutics Curium Pharma, F. Hoffman-La Roche, Eli Lilly USA, Sanofi-Aventis and Theravance. K.M. declares support from his institution (Institute for Neurodegenerative Disorders) from the MJFF, and consultancies for Invicro, Xing Imaging, Ixico, the MJFF, Roche, Calico, Coave, Neuron23, Orbimed, Biohaven, Sanofi, Koneksa, Merck, Lilly, Inhibikase, Neuramedy, IRLabs and Prothena. D.G. has served as a consultant for GE Healthcare, Eisai and Biogen. K.P. is a scientific advisor to Amprion and has served as a consultant for Curasen, Novartis, Biohaven and Neuron23.
